Stock Analysis
Medley (TSE:4480) Second Quarter 2024 Results
Key Financial Results
- Revenue: JP¥8.76b (up 40% from 2Q 2023).
- Net income: JP¥1.54b (up 1.0% from 2Q 2023).
- Profit margin: 18% (down from 24% in 2Q 2023).
- EPS: JP¥47.47 (up from JP¥47.30 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medley Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 29%.
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Japan.
Performance of the Japanese Healthcare Services industry.
The company's shares are down 13% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Medley that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4480
Medley
Operates platforms for recruitment and medical businesses in Japan and the United States.